Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Proposed legislation could deter Chinese biotechs from listing in U.S.

U.S. bill seeking to tighten auditing rules for foreign companies could be win for HKSE

A Senate bill seeking to tighten auditing rules for U.S.-listed foreign companies could end up pushing more Chinese biotechs to go public in Hong Kong. But months of protests and a proposed new national security law under consideration by Beijing could scuttle the opportunity.

The Holding Foreign Companies Accountable Act, which the U.S. Senate passed with unanimous consent Wednesday, would prohibit securities of a

Read the full 636 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers